Patent US6979688B2 successfully refreshed from Google Patents.
US6979688B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment method against side-effects of chemotherapy
Assignee: Asymmetric Therapeutics LLC
•
Filing: 2003-10-10
•
Granted: 2005-12-27
•
Expires: 2023-10-10
Abstract
Abstract A method and composition is provided for organ rescue wherein a specific counter-measure is applied locally to a tissue at risk for or exhibiting an adverse side effect of a cancer treatment. More particularly, the method and composition is directed at controlling Hand-Foot Syndrome, a painful redness and cracking of the skin of the hands and feet which can occur with systemic treatment with 5-fluorouracil or a precursor thereof. Uracil ointment is applied to the skin of the hands and feet to prevent Hand-Foot Syndrome which can occur from systemic administration of 5-fluorouracil (or precursor thereof) as cancer treatment.
Inventors
- 👤 John P. Ford
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 23:22
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/337; A61K31/395; A61K31/495; A61K31/505; A61K31/513; A61K31/555; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K31/7042; A61K31/7052; A61K31/706; A61K31/7064; A61K31/7068; A61K31/7072; A61P; A61P35/00
Claims Analysis
Total Claims: 66
Claim 1
Independent Claim
60 words
A method of reducing cutaneous side-effects of systemic therapy with 5-fluorouracil (5-FU) or a precursor of 5-FU, the method comprising: applying uracil topically to the skin of a patient being treated concurrently and systemically with 5-fluorouracil (5-FIT) or a precursor of 5-FU in an amount effective to reduce, at the site of topical uracil administration, the development of cutaneous side-effects.
Claim 2
Independent Claim
60 words
A method of reducing cutaneous side-effects of systemic therapy with 5-fluorouracil (5-FU) or a precursor of 5-FU, the method comprising: applying uracil topically to the skin of a patient being treated concurrently and systemically with 5-fluorouracil (5-FIT) or a precursor of 5-FU in an amount effective to reduce, at the site of topical uracil administration, the development of cutaneous side-effects.
Claim 3
Dependent Claim
14 words
The method of claim 1 , wherein the systemic therapeutic is a 5-fluorouracil precursor.
Claim 4
Dependent Claim
11 words
The method of claim 2 , wherein said precursor is capecitabine.
Claim 5
Dependent Claim
20 words
The method of claim 1 , wherein uracil is applied in a composition that further comprises a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
23 words
The method of claim 4 , wherein uracil is present within said composition at a concentration by weight of at least about 0.1%.
Claim 7
Dependent Claim
23 words
The method of claim 5 , wherein uracil is present within said composition at a concentration by weight of at least about 1%.
Claim 8
Dependent Claim
24 words
The method of claim 4 , wherein uracil is present within said composition at a concentration by weight of no more than about 60%.
Claim 9
Dependent Claim
24 words
The method of claim 7 , wherein uracil is present within said composition at a concentration by weight of no more than about 5%.
Claim 10
Dependent Claim
21 words
The method of claim 4 , wherein uracil is present within said composition at a concentration by weight of about 1%.
Claim 11
Dependent Claim
15 words
The method of claim 4 , wherein said composition is either anhydrous or an emulsion.
Claim 12
Dependent Claim
12 words
The method of claim 10 , wherein said composition is an emulsion.
Claim 13
Dependent Claim
27 words
The method of claim 4 , wherein said composition is selected from the group consisting of creams, lotions, ointments, aerosol sprays, roll-on liquids, roll-on sticks and pads.
Claim 14
Dependent Claim
34 words
The method of claim 4 , wherein said carrier comprises at least one agent selected from the group consisting of emollients, water, inorganic powders, foaming agents, emulsifiers, fatty alcohols, fatty acids, and combinations thereof.
Claim 15
Dependent Claim
14 words
The method of claim 13 , wherein said carrier comprises at least one emollient.
Claim 16
Dependent Claim
23 words
The method of claim 14 , wherein said at least one emollient is selected from the group consisting of polyols, esters, and hydrocarbons.
Claim 17
Dependent Claim
41 words
The method of claim 15 , wherein said polyol is selected from the group consisting of propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, 1,2,6-hexanetriol, glycerin, ethoxylated glycerin, propoxylated glycerin, xylitol, and mixtures thereof.
Claim 18
Dependent Claim
27 words
The method of claim 15 , wherein said ester is selected from the group consisting of alkyl esters of fatty acids having 10 to 20 carbon atoms.
Claim 19
Dependent Claim
49 words
The method of claim 15 , wherein said ester is selected from the group consisting of hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, diisopropyl adipate, diisohexyl adipate, dihexyldecyl adipate, diisopropyl sebacate, lauryl lactate, myristyl lactate and cetyl lactate.
Claim 20
Dependent Claim
15 words
The method of claim 15 , wherein said ester is a C12-C15 alcohol benzoate ester.
Claim 21
Dependent Claim
17 words
The method of claim 19 , wherein said ester is oleyl myristate, oleyl stearate or oleyl oleate.
Claim 22
Dependent Claim
19 words
The method of claim 15 , wherein said ester is a fatty acid ester of an ethoxylated fatty alcohol.
Claim 23
Dependent Claim
14 words
The method of claim 15 , wherein said ester is a polyhydric alcohol ester.
Claim 24
Dependent Claim
65 words
The method of claim 22 , wherein said ester is selected from the group consisting of ethylene glycol mono- and di-fatty acid esters, diethylene glycol mono- and di-fatty acid esters, polyethylene glycol (200-6000) mono- and di-fatty acid esters, polyglycerol poly-fatty esters, ethoxylated glyceryl monostearate, 1,3-butylene glycol monostearate, 1,3-butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters.
Claim 25
Dependent Claim
13 words
The method of claim 15 , wherein said ester is a wax ester.
Claim 26
Dependent Claim
24 words
The method of claim 24 , wherein said wax ester is selected from the group consisting of beeswax, spermaceti, myristyl myristate and stearyl stearate.
Claim 27
Dependent Claim
13 words
The method of claim 15 , wherein said ester is a sterol ester.
Claim 28
Dependent Claim
13 words
The method of claim 13 , wherein said carrier comprises an inorganic powder.
Claim 29
Dependent Claim
34 words
The method of claim 27 , wherein said inorganic powder is selected from the group consisting of clays, talc, mica, silica, alumina, zeolites, sodium sulfate, sodium bicarbonate, sodium carbonate, calcium sulfate and mixtures thereof.
Claim 30
Dependent Claim
13 words
The method of claim 4 , wherein said carrier comprises an aerosol propellant.
Claim 31
Dependent Claim
26 words
The method of claim 29 , wherein said propellant is selected from the group consisting of propane, butane, isobutene, pentane, isopropane, fluorocarbons, dimethylether and mixtures thereof.
Claim 32
Independent Claim
30 words
The method of any one of claims 1 or 2 , wherein uracil is applied topically to the skin of the foot, the hand, or both the foot and hand.
Claim 33
Independent Claim
59 words
A method of treating breast or colorectal cancer with reduced cutaneous side-effects, the method comprising: systemically administering 5-fluorouracil (5-FU) or a precursor of 5-FU to a patient having breast or colorectal cancer; and concurrently applying uracil topically to the patient's skin in an amount effective to reduce, at the site of topical uracil administration, the development of cutaneous side-effects.
Claim 34
Independent Claim
59 words
A method of treating breast or colorectal cancer with reduced cutaneous side-effects, the method comprising: systemically administering 5-fluorouracil (5-FU) or a precursor of 5-FU to a patient having breast or colorectal cancer; and concurrently applying uracil topically to the patient's skin in an amount effective to reduce, at the site of topical uracil administration, the development of cutaneous side-effects.
Claim 35
Dependent Claim
15 words
The method of claim 32 , wherein the systemically administered therapeutic is a 5-fluorouracil precursor.
Claim 36
Dependent Claim
11 words
The method of claim 33 , wherein said precursor is capecitabine.
Claim 37
Dependent Claim
20 words
The method of claim 32 , wherein uracil is applied in a composition that further comprises a pharmaceutically acceptable carrier.
Claim 38
Dependent Claim
23 words
The method of claim 35 , wherein uracil is present within said composition at a concentration by weight of at least about 0.1%.
Claim 39
Dependent Claim
23 words
The method of claim 36 , wherein uracil is present within said composition at a concentration by weight of at least about 1%.
Claim 40
Dependent Claim
24 words
The method of claim 35 , wherein uracil is present within said composition at a concentration by weight of no more than about 60%.
Claim 41
Dependent Claim
24 words
The method of claim 38 , wherein uracil is present within said composition at a concentration by weight of no more than about 5%.
Claim 42
Dependent Claim
21 words
The method of claim 35 , wherein uracil is present within said composition at a concentration by weight of about 1%.
Claim 43
Dependent Claim
15 words
The method of claim 35 , wherein said composition is either anhydrous or an emulsion.
Claim 44
Dependent Claim
12 words
The method of claim 41 , wherein said composition is an emulsion.
Claim 45
Dependent Claim
27 words
The method of claim 35 , wherein said composition is selected from the group consisting of creams, lotions, ointments, aerosol sprays, roll-on liquids, roll-on sticks and pads.
Claim 46
Dependent Claim
34 words
The method of claim 35 , wherein said carrier comprises at least one agent selected from the group consisting of emollients, water, inorganic powders, foaming agents, emulsifiers, fatty alcohols; fatty acids, and combinations thereof.
Claim 47
Dependent Claim
14 words
The method of claim 44 , wherein said carrier comprises at least one emollient.
Claim 48
Dependent Claim
23 words
The method of claim 45 , wherein said at least one emollient is selected from the group consisting of polyols, esters, and hydrocarbons.
Claim 49
Dependent Claim
41 words
The method of claim 46 , wherein said polyol is selected from the group consisting of propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, 1,2,6-hexanetriol, glycerin, ethoxylated glycerin, propoxylated glycerin, xylitol, and mixtures thereof.
Claim 50
Dependent Claim
27 words
The method of claim 46 , wherein said ester is selected from the group consisting of alkyl esters of fatty acids having 10 to 20 carbon atoms.
Claim 51
Dependent Claim
49 words
The method of claim 46 , wherein said ester is selected from the group consisting of hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, diisopropyl adipate, diisohexyl adipate, dihexyldecyl adipate, diisopropyl sebacate, lauryl lactate, myristyl lactate and cetyl lactate.
Claim 52
Dependent Claim
15 words
The method of claim 46 , wherein said ester is a C12-C15 alcohol benzoate ester.
Claim 53
Dependent Claim
17 words
The method of claim 50 , wherein said ester is oleyl myristate, oleyl stearate or oleyl oleate.
Claim 54
Dependent Claim
19 words
The method of claim 46 , wherein said ester is a fatty acid ester of an ethoxylated fatty alcohol.
Claim 55
Dependent Claim
14 words
The method of claim 46 , wherein said ester is a polyhydric alcohol ester.
Claim 56
Dependent Claim
65 words
The method of claim 53 , wherein said ester is selected from the group consisting of ethylene glycol mono- and di-fatty acid esters, diethylene glycol mono- and di-fatty acid esters, polyethylene glycol (200-6000) mono- and di-fatty acid esters, polyglycerol poly-fatty esters, ethoxylated glyceryl monostearate, 1,3-butylene glycol monostearate, 1,3-butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters.
Claim 57
Dependent Claim
13 words
The method of claim 46 , wherein said ester is a wax ester.
Claim 58
Dependent Claim
24 words
The method of claim 55 , wherein said wax ester is selected from the group consisting of beeswax, spermaceti, myristyl myristate and stearyl stearate.
Claim 59
Dependent Claim
13 words
The method of claim 46 , wherein said ester is a sterol ester.
Claim 60
Dependent Claim
13 words
The method of claim 44 , wherein said carrier comprises an inorganic powder.
Claim 61
Dependent Claim
34 words
The method of claim 58 , wherein said inorganic powder is selected from the group consisting of clays, talc, mica, silica, alumina, zeolites, sodium sulfate, sodium bicarbonate, sodium carbonate, calcium sulfate and mixtures thereof.
Claim 62
Dependent Claim
13 words
The method of claim 35 , wherein said carrier comprises an aerosol propellant.
Claim 63
Dependent Claim
26 words
The method of claim 60 , wherein said propellant is selected from the group consisting of propane, butane, isobutene, pentane, isopropane, fluorocarbons, dimethylether and mixtures thereof.
Claim 64
Independent Claim
30 words
The method of any one of claims 32 - 61 , wherein uracil is applied topically to the skin of the foot, the hand, or both the foot and hand.
Claim 65
Independent Claim
17 words
The method of any one of claims 32 - 61 , wherein the cancer is breast cancer.
Claim 66
Independent Claim
17 words
The method of any one of claims 32 - 61 , wherein the cancer is colorectal cancer.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2008-12-26 | 2009-06-27 | 2009-12-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2012-12-26 | 2013-06-27 | 2013-12-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2016-12-26 | 2017-06-27 | 2017-12-27 | $7700.00 | Window Closed / Lapsed |